(Q53026185)
English
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
scientific article published on 13 February 2015
Statements
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. (English)
Joachim Yahalom
Steven Horwitz
Andrew Zelenetz
Alison J Moskowitz
Heiko Schöder
Susan J McCall
Stephanie Y Fox
John Gerecitano
Ravinder Grewal
Rachel Kobos
Anita Kumar
M Lia Palomba
Miguel-Angel Perales
Carol S Portlock
Craig Sauter
Neerav Shukla
Peter Steinherz
David Straus
Tanya Trippett
Anas Younes
Craig H Moskowitz
13 February 2015
16
3
284-292